newsfilter
← Earnings
Earnings Releases·

Arcturus Therapeutics — Third Quarter 2026 Earnings Summary

  • Q3 2026 total revenue rose to $18.3 million from $17.2 million in the prior year period, while the nine-month total fell to $23.3 million from $74.8 million; net loss narrowed to $7.4 million ($0.26/share) for the quarter versus $13.4 million ($0.49/share) previously, though the nine-month loss widened to $58.2 million from $36.7 million.
  • Cash and cash equivalents decreased to $184.8 million as of September 30, 2026, from $230.9 million at year-end 2025, with management projecting a cash runway extending beyond two years through 2028.
  • Strategic milestones include the successful integration of the myNEO acquisition, a $12.0 million settlement payment from CSL Seqirus, and the transfer of KOSTAIVE® marketing authorization in the EU and UK to facilitate 2027 commercial activities.
  • Pipeline progress features ARCT-810 demonstrating meaningful biomarker activity in Phase 2, the introduction of the LUNAR 2.0™ platform with ARCT-2601 scheduled for Phase 2 dosing in Q1 2027, and an IND submission for the PKU program planned for H2 2027.
Company
ARCTURUS THERAPEUTICS HOLDINGS INC
Sector
Healthcare
Industry
Biotechnology